已发表论文

低水平的肿瘤抑制剂候选药物 3 预测肝细胞癌患者预后不良

 

Authors Sheng XR, Xing SG, Wang RD, Chen K, Jia WD

Received 6 October 2017

Accepted for publication 9 January 2018

Published 21 February 2018 Volume 2018:11 Pages 909—917

DOI https://doi.org/10.2147/OTT.S153381

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Carlos Vigil Gonzales

Purpose: The tumor suppressor candidate 3 (TUSC3 ) has been considered to be closely associated with the occurrence, development and invasion of various malignant tumors. However, the expression of TUSC3  in hepatocellular carcinoma (HCC) tissues remains ambiguous. The purpose of this research was to investigate the expression of TUSC3  in HCC tissues and analyze the relationship between TUSC3  levels and clinicopathological characteristics and prognosis of HCC patients.
Materials and methods: Immunohistochemistry was used to detect the expression of TUSC3 in HCC and the corresponding para-cancerous tissues from 92 samples of HCC patients. mRNA and protein expression levels of TUSC3  were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays in 25 paired HCC and corresponding adjacent nontumor tissues. Furthermore, statistical analysis was applied to evaluate the correlation between TUSC3 level and the clinicopathological features and prognosis of HCC patients.
Results: Immunohistochemical assay indicated that the expression of TUSC3  was significantly lower in HCC tissues when compared with the corresponding para-cancerous tissues (χ 2=11.512, =0.001). The analysis of clinicopathological characteristics showed that low expression of TUSC3  in HCC tissues was significantly associated with Edmondson grade, Barcelona Clinic Liver Cancer stage and tumor size (=0.008, 0.009 and 0.020, respectively). Univariate analysis showed that the expression of TUSC3  was strongly correlated with overall survival (OS) and disease-free survival (DFS) after radical surgery in HCC patients (<0.001, <0.001, respectively). Multivariate analysis revealed that the TUSC3  level was an independent risk factor for OS and DFS in HCC patients (=0.001, <0.001, respectively). Results of qRT-PCR and Western blot assays indicated that the level of TUSC3  in HCC tissues was significantly lower than that in the corresponding adjacent noncancerous tissues (<0.01, <0.001).
Conclusion: The expression of TUSC3  in HCC was significantly downregulated and was correlated with tumor progression and prognosis, which could be used as an independent predictor of prognosis in HCC patients.
Keywords: TUSC3 , hepatocellular carcinoma, prognosis, immunohistochemistry, overall survival